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patients. We sought to evaluate aspirin and clopidogrel response in elderly
patients soon after PCI and on chronic maintenance treatment.
Methods and Results: We prospectively included 93 elderly patients (≥
75 years) who underwent PCI from January 2008 to April 2009. All patients
were treated with aspirin and clopidogrel. We used a standardized point of
care assay VerifyNow® aspirin and VerifyNow® clopidogrel P2Y12 to mea-
sure aspirin and clopidogrel responsiveness with cut-offs previously validated
in clinical trials. Measurements were performed in-hospital after PCI (T1) and
5-6 weeks later (T2) when the patients had been on maintenance therapy (75
mg aspirin plus 75 mg clopidogrel once a day) for at least 1 week. Aspirin
non/poor responders were found in 10 % of patients at T1 and in 14% at T2.
Clopidogrel non/poor response was noted in 32% of patients at T1 and in 68%
at T2. Changes in platelet reactivity to clopidogrel was significant from T1 to
T2 (p-value <0.001), but not significant for aspirin. Multivariate analysis
revealed low hematocrit (Ht) to be independently associated with clopidogrel
non responsiveness at T1 (OR 2.99; 95% CI 1.04-8.59; p-value=0.042 for Ht
<35%) and T2 (OR 2.74; 95% CI 1.08-6.93; p-value=0.033 for Ht <40%).
Conclusions: The rate of biological non/poor response to dual antiplatelet
therapy in elderly patients soon after PCI was close to that reported in younger
patients. In contrast, there was high residual platelet reactivity under chronic
treatment with 75 mg of clopidogrel (almost two-thirds).
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Transient cortical blindness after coronary angiography : 2 cases
report. 
Marie Solange Ndom, Najat Mouine 
Hôpital Militaire de Rabat, Cardiologie, Rabat, Maroc
Transient cortical blindness is rarely encountered after coronary angiog-
raphy or angioplasty. This paper reports 2 cases of transient cortical blindness
that occurred immediately after coronary angiography in 2 cases who admitted
for ischemic heart disease. Ophthalmological examination was normal and
neurological examination demonstrated cortical blindness and the absence of
any focal neurological deficit.
A computed tomography scan of the brain did not reveal any abnormality.
Sight returned spontaneously within 2 days and their vision gradually
improved. A search of the current literature for reported cases of transient cor-
tical blindness suggested that this is a rarely encountered complication of cor-
onary angiography and appears to probably carry no increased risk. 
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Impact of Niacin therapy on endothelial vasomotricity in patients with
low HDL shortly after an acute coronary syndrome
Meyer Elbaz, Thibault Lhermusier, Vincent Bataille, Vanina Bongard,
Jérôme Roncalli, A Bura-Riviere, J Ferrières, Didier Carrié, Michel Gali-
nier, J-P Cambou
CHU Rangueil, Cardiovascular and Metabolic Pole, Toulouse, France
Purpose: Usefullness of Niacin in subjects with stable coronary heart dis-
ease [CHD], low HDL and endothelial dysfunction [ED] remains controver-
sial. Furthermore, benefits of its prescription after an acute coronary syndrome
[ACS] in pts with low HDL and ED is unknown.
Methods: The EVAN-ACS study was a double-blind randomised placebo-
controlled trial aiming at the evaluation of effects of Niacin on endothelial
function in subjects with low HDL (<0.4 g/l) and ED who recently suffered
from an ACS. Pts were screened over a 18 months period. Flow Mediated
Dilation [FMD] of the brachial artery was measured in the 7 days following
the ACS, and subjects with FMD<7% were randomized either to the Treat-
ment Group [TG] (Niacin 1000 mg/d) or to the Placebo Group [PG]. After
12 weeks, new measurement of FMD was performed.
Results: 75 pts with ED were randomised. Median age was 51 (45-61) and
92.6% of the pts were men. No significant baseline difference existed between
the two groups for age, gender, smoking, blood pressure, plasma lipoprotein
levels, CRP or FMD. After 12 weeks, FMD had significantly increased both
in the TG (median absolute change: +3.6%, p<0.001) and in the PG (+2.1%,
p<0.001), but the difference between the two groups was not significant
(p=0.87). In the same way, CRP, LDL-C and triglycerides significantly
decreased and HDL significantly increased in both groups, but these changes
were not statistically different from the TG to the PG (median absolute change
of CRP : -4.2 and –2.7 mg/l respectively in the TG and in the PG, p=0.63 /
LDL-C: -0.3 and -0.4 g/l mmol/l or mg/dl, p=0.84 / triglycerides: -0.51 and –
0.52 g/l, p=0.63 / HDL-C: +0.07 and +0.02 g/l, p=0.09).
Conclusions: In this trial, conducted in subjects with ED shortly after an
ACS, FMD increased both in the Niacin treated group and the placebo group,
but the extent of this rise was not significantly different. Larger studies and/or
higher niacin doses are required to better address this important topic.
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Purpose : Percutaneous treatment of unprotected left main coronary artery
(ULMCA) disease is progressively gaining acceptance in light of the first
results from drug-eluting stent registries or randomized trial. We thus assessed
early and mid-term results of patients treated for ULMCA disease in the
FRIEND registry.
Methods: After ethical committee approval and informed consent, all con-
secutive patients with unprotected left main stenoses treated with Taxus stents
were included in a multicenter prospective study from 23 centers. Major
adverse cardiac and cerebro-vascular events (MACCE) were adjudicated at
1,6,12,18 and 36 months by an independent committee. Immediate and 9-
month angiographic results were assessed by a central core lab (Corysis, St-
Denis, France). 
Results: From December 2005 to July 2006, 151 patients (pts) were
included, mean age 68 ± 11 years, 83 % male, 41 % unstable angina, 3 % dia-
betics, 24 % 3-vessel disease.The mean Euroscore was 4.1 ± 2.8. The LM ref-Abnormal aspect of the occipital lobes 
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erence diameter was 3.9 ± 0.5mm. LM lesion was non distal in 34 %, and
distal in 66 % of pts. In this group, 72 % were located at the bifurcation
including LAD, LCX or both ostia affected. All patients were successfully
treated on the LM (stent length 15.7 ± 5.2 mm) and a final kissing balloon
inflation was performed in 90%. Apart from the LM stenosis, a total of 1.2 ±
0.8 lesions were treated during the hospitalisation (total stent length 47 ±
16mm). In-hospital MACCE rate was 4.5 % with 2.6% of mortality ; at 9-
month follow-up (FU), the global rate of event-free survival was 93.5 % with
a very low angiographic restenosis rate of 3 %. Between 9 and 36-month clin-
ical FU, there were one sudden death, 6 extra-cardiac deaths (total mortality
7%), one recurrent angina and 1 cardiac failure. Event free survival was 84 %.
Conclusion: LM PCI using the TAXUS stent is feasible and safe at long-
term follow-up. Stenting deserves to be considered a safe and effective alter-
native to CABG in institutions performing large numbers of PCIs. 
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Introduction: Several clinical trials have validated the effectiveness of
drug eluting stents (DES) and its benefit comparing to bare-metal stent for res-
tenosis rate reduction after angioplasty. But the major disadvantage of DES is
thrombosis. The aim of this study is to describe clinical and angiographic out-
comes of DES implantation in Sfax Cardiology Departments (public and pri-
vate centers). 
Patients and methods: Our study is retrospective including 619 patients
undergoing percutaneous angioplasty by 769 eluding stents during the period
between juillet 2003 and June 2009.
Results: The mean age was 63,25 years and most patients were men
(80,7%). The majority of patients (61, 6%) were diabetic. Most patients (46,
3%) had multivessel disease. Coronary lesion sites were located mainly on the
left descending coronary artery at 71, 4%. The mean diameter stent was 2, 93
± 0,37 mm, and the mean length was 26,95± 6,91mm. Coronary lesion was in
the most time long (in 43,1%). We used Taxus stents in 81,4% of cases. The
stenting was direct in 72,1% of procedures, and after dilatation in 22 proce-
dures%. A post inflation was achieved in 11,3% of procedures. The mean of
pression inflation was 14, 29 mmhg. The angiographic success was noted in
100%. The mean follow-up was 18, 26 months. Acute instent thrombosis
occurred in 3,7% (23 patients/619 patients). One case of acute thrombosis, 21
cases of subacute thrombosis, one case of late thrombosis, no case of very-
late  thrombosis was noted. On the Follow up , an angiographic control was
performed in 8,3% des cas (49 patients). A restenosis in stent was noted in
16% and new lesions were noted in 3,6% of cases. MACE rate was 10,2%
with 2,5% of mortality.
Conclusion: The high price of drug eluting stents relative to bare stents
has been an obstacle to widespread utilization of drug eluting stents in our ter-
tiary region. These latter are more interesting for diabetic persons and complex
lesions but they are limited by the risk of acute and late thrombosis. 
Acknowledgement: cardiologists of the region of Sfax 
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Introduction: Normal renal function has been Shown in epidemiological
studies and clinical trials to be an independent predictor of survival.
Objective: To determine whether creatinine clearance at the time of hos-
pital admission is an independent predictor of hospital mortality and adverse
outcomes in patients with ST -segment elevation myocardial infarction(
STEMI).
Patients: 231 patients hospitalized with STEMI in our institution between
January 2005 to December 2006.
In-hospital outcomes were compared for patients with creatinine clearance
rates of > 60 ml/min (normal renal function) and ≤60 ml/min (moderate and
severe Baseline Renal Dysfunction, BRD).
Results: Patients with BRD were older, were more likely to be women, and
presented to with more comorbidites. 
Patients with BRD had presented more ischemic atrial fibrillation (p=0.033).
A greater number of patients with BRD had impaired left ventricle systolic
performance, so this patients had more presented acute heart failure (p=0.008),
and cardiogenic shock (p=0.017).
Patients with worsened renal function had presented more mechanical compli-
cations: 
-free wall rupture and apical ventricular septal defect , in two separate cases
,following anterior myocardial infarction , leading to immediate death of these
two patients.
-ischemic mitral regurgitation in one case
The in hospital death rate of BRD patients was 6.6%, compared with 0.9% for
non BRD patients.
In comparison with patients with normal or minimally impaired renal function,
patients with moderate renal dysfunction were seven times more likely to die
(odds ratio 7, 09, 95% confidence interval 0.7 to 68) after adjustment for other
potentially confounding Variables.
The risk of bleeding episodes was increased in patients with worsened renal
functionOnly one patient, with moderate renal dysfunction, had an ischemic
stroke.
Conclusion: In patients with ACS, creatinine clearance is an important
independent predictor of hospital death. 
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Ischemic heart disease is the most common cause of death in patients with
chronic kidney disease (CKD). Patients with CKD who develop an ST eleva-
tion myocardial infarction(STEMI) have a poor prognosis, with >70% mor-
tality at 2 years. Despite this heavy burden of disease, the optimal
management of ACS in this patient population is unknown. Our goal was to
compare the effect of coronary revascularization or medical therapy alone on
the long-term survival of patients with CKD presenting with STEMI. From
2005 to 2007, data were prospectively collected on 231 patients admitted to a
coronary care unit with the diagnosis of STEMI. Of these, 112 had preserved
renal function, and 119 had significant renal dysfunction, as defined by the
National Kidney Foundation in the Kidney Disease Outcomes Quality Initia-
tive classification of kidney function as an estimated glomerular filtration rate
of <60 ml/min/1.73 m(2).
Long-term survival was assessed and outcomes were compared according
to whether patients were treated with medical therapy alone or if they under-
went a percutaneous or surgical revascularization procedure. Follow-up infor-
mation was available in 68 patients up to 1 year after the index hospitalization.
Of the 119 patients with significant renal dysfunction, ten underwent coronary
artery bypass surgery, 77underwent percutaneous coronary revascularization,
eight underwent a diagnostic cardiac catheterization and were subsequently
treated medically. Percutaneous coronary revascularization was associated
with superior long-term survival. Surgical revascularization was an indepen-
dent predictor of MACCE at one tear after index hospitalization ((p=0.03,
HR= 2.760; 95% CI 1.101-6.920).
In conclusion, patients with severe CKD and STEMI had improved long-
term survival when treated with percutaneous coronary revascularization.
